Mereo BioPharma Group PLC | Mutual Funds
Mutual Funds that own Mereo BioPharma Group PLC
CF Woodford Equity Income
16,853,667
23.69%
0
0.77%
07/31/2018
Invesco Perpetual UK Invt. Ser. - High Income
13,529,377
19.01%
0
0.39%
03/29/2018
9,885,234
13.89%
-20,488
3.13%
07/31/2018
Invesco Perpetual UK 2 Invt. Series - UK Strategic Income Fund
3,818,121
5.37%
-1,317,385
2.27%
03/29/2018
Invesco Perpetual UK 2 Invt. Series - Income Fund
1,801,678
2.52%
1,300,000
0.11%
03/29/2018
Marlborough UK Micro Cap Growth Fund
1,599,363
2.25%
5,920
0.37%
03/29/2018
Marlborough Special Situations Fund
1,234,076
1.73%
4,568
0.21%
03/29/2018
Old Mutual Woodford Equity Income Fund
1,070,770
1.51%
0
1.91%
07/31/2018
City Financial Absolute Equity Fund
544,725
0.77%
0
0.63%
09/29/2017
| Address |
1 Cavendish Place
London Greater London W1G 0QF
United Kingdom
|
|
Employees
|
- |
| Website |
http://mereobiopharma.com/ |
| Updated |
07/08/2019 |
| Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with Osteogenesis Imperfecta, Alpha-1 Antitrypsin Deficiency, Hypogonadotropic Hypogonadism in obese men, and Acute Exacerbations of Chronic Obstructive Pulmonary Disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom. |
